Immunitybio Inc annual revenue for fiscal TTM was $165 million, an increase of 46.0% from $113 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Revenue (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $165M | $113M | $15M | $1M | $0M | $1M | $1M | $0M | $0M | $0M | $0M | $0M | $1M | $1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Revenue (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $51M | $44M | $38M | $32M | $26M | $17M | $8M | $6M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More IBRX metrics: Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All IBRX financial statements → Interactive IBRX charts →
About TickerBase · Data methodology & sources · Privacy · Terms